X hits on this document

Powerpoint document

Clevidipine Phase III Studies: Perioperative Hypertension - page 64 / 65

171 views

0 shares

0 downloads

0 comments

64 / 65

IMPORTANT SAFETY INFORMATION

Cleviprex is intended for intravenous use. Titrate drug depending on the response of the individual patient to achieve the desired blood pressure reduction. Monitor blood pressure and heart rate continually during infusion, and then until vital signs are stable. Patients who receive prolonged Cleviprex infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.

Cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products; defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia; and in patients with severe aortic stenosis.

Hypotension and reflex tachycardia are potential consequences of rapid upward titration of Cleviprex. Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure. Monitor heart failure patients carefully. Cleviprex gives no protection against the effects of abrupt beta-blocker withdrawal.

Clevidipine Product Information August 2008; The Medicines Company

Cleviprex is a diydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is  not feasible or not desirable. Please see full prescribing information.

Document info
Document views171
Page views171
Page last viewedSun Dec 04 10:49:53 UTC 2016
Pages65
Paragraphs1351
Words4734

Comments